NBW Capital LLC increased its position in shares of Repligen Corporation (NASDAQ:RGEN) by 93.8% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 43,909 shares of the biotechnology company’s stock after purchasing an additional 21,254 shares during the period. NBW Capital LLC owned approximately 0.12% of Repligen Corporation worth $1,820,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other large investors have also recently added to or reduced their stakes in the stock. Ameritas Investment Partners Inc. acquired a new position in Repligen Corporation in the 1st quarter valued at $103,000. Victory Capital Management Inc. raised its holdings in Repligen Corporation by 76.6% in the 1st quarter. Victory Capital Management Inc. now owns 3,400 shares of the biotechnology company’s stock valued at $120,000 after acquiring an additional 1,475 shares in the last quarter. Quantbot Technologies LP acquired a new position in Repligen Corporation in the 2nd quarter valued at $120,000. Oppenheimer Asset Management Inc. acquired a new position in Repligen Corporation in the 2nd quarter valued at $123,000. Finally, JPMorgan Chase & Co. raised its holdings in Repligen Corporation by 31.9% in the 1st quarter. JPMorgan Chase & Co. now owns 3,755 shares of the biotechnology company’s stock valued at $133,000 after acquiring an additional 908 shares in the last quarter. 97.91% of the stock is owned by institutional investors and hedge funds.
Shares of Repligen Corporation (NASDAQ RGEN) traded up 0.29% during trading on Friday, reaching $38.33. The company’s stock had a trading volume of 269,728 shares. The stock has a 50-day moving average of $41.66 and a 200-day moving average of $39.55. Repligen Corporation has a 52-week low of $26.16 and a 52-week high of $46.81. The stock has a market cap of $1.43 billion, a P/E ratio of 75.01 and a beta of 1.18.
Repligen Corporation (NASDAQ:RGEN) last posted its earnings results on Thursday, August 3rd. The biotechnology company reported $0.20 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.15 by $0.05. The firm had revenue of $32.40 million for the quarter, compared to the consensus estimate of $31.72 million. Repligen Corporation had a return on equity of 9.90% and a net margin of 15.61%. The business’s quarterly revenue was up 11.0% on a year-over-year basis. During the same quarter in the prior year, the business posted $0.16 earnings per share. Analysts predict that Repligen Corporation will post $0.59 earnings per share for the current fiscal year.
Several brokerages have weighed in on RGEN. Janney Montgomery Scott lifted their price objective on Repligen Corporation from $42.00 to $47.00 in a report on Friday, June 23rd. TheStreet raised Repligen Corporation from a “c+” rating to a “b-” rating in a report on Friday, August 11th. BidaskClub raised Repligen Corporation from a “hold” rating to a “buy” rating in a report on Wednesday, August 9th. First Analysis raised Repligen Corporation from an “equal weight” rating to an “overweight” rating and set a $47.00 price objective for the company in a report on Monday, October 2nd. Finally, Zacks Investment Research raised Repligen Corporation from a “hold” rating to a “buy” rating and set a $43.00 price objective for the company in a report on Thursday. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus target price of $45.40.
Repligen Corporation Company Profile
Repligen Corporation is a bioprocessing company. The Company is focused on the development, manufacture and commercialization of products used to improve the interconnected phases of the biological drug manufacturing process. The Company’s portfolio includes protein products, chromatography products, and filtration products.
Receive News & Ratings for Repligen Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen Corporation and related companies with MarketBeat.com's FREE daily email newsletter.